<DOC>
	<DOCNO>NCT02806544</DOCNO>
	<brief_summary>This study evaluate feasibility efficacy neoadjuvant tamoxifen patient locally advance hormone receptor positive breast cancer low/middle income country .</brief_summary>
	<brief_title>Neoadjuvant Tamoxifen Locally Advanced Breast Cancer Low/Middle Income Country</brief_title>
	<detailed_description>This single arm feasibility study neoadjuvant tamoxifen locally advance hormone receptor positive breast cancer low-resource set middle-income country ( Guatemala ) . Patients treat tamoxifen four six week , on-treatment biopsy ass Ki-67 . If Ki-67 le equal 10 % , patient continue tamoxifen total 4 month ; Ki-67 great 10 % clinical progression , patient take study . The study evaluate proportion patient treat four month tamoxifen undergo definitive surgery clinical pathologic response rate .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>Patient evaluate treated INCAN Patients must provide informed consent Patient must ≥ 18 year age . Life expectancy ≥ 6 month Clinical locally advance breast cancer ( Stage IIB III ) Pathologically confirm diagnosis estrogen receptor ( ER ) positive progesterone receptor ( PR ) positive breast cancer ER PR Allred Score &gt; 4 Patient must ECOG Performance Status 02 Patients must able swallow retain oral medication Patient must receive prior chemotherapy , radiation therapy , biologic therapy invasive breast cancer within past five year Patient must pregnant nursing Patient must prior malignancy except adequately treat basal cell ( squamous cell ) skin cancer , situ cervical cancer cancer patient diseasefree five year . Women childbearing age unable unwilling use contraception</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Breast neoplasm</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Locally advanced breast cancer</keyword>
	<keyword>Neoadjuvant endocrine therapy</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Low middle income country</keyword>
</DOC>